CRISPR Therapeutics (CRSP) Director George Sells $720K of Stock

CRISPR Therapeutics AG director Simeon George sold 14,514 shares of the gene editing company on October 14, 2026. The transaction was revealed in a Form 4 filing submitted to the Securities and Exchange Commission. The shares were disposed of at an average price of $49.33 per share, bringing the total value of the sale to approximately $720,373. This pre-arranged sale was carried out pursuant to a Rule 10b5-1 trading plan. Shares of the company closed at $50.22 on the day of the transaction. Following this transaction, George holds remaining shares in the company.

Inside Simeon George's CRISPR Trade

The planned sale involved 14,514 shares at a price of $49.63, for a total value of $720,373. Form 4 filings require insiders to disclose open-market transactions within two business days. This sale follows earlier insider trades at the firm earlier in the autumn.

Other Institutional Activity in CRISPR Therapeutics

ARK Investment Management, LLC reduced its stake by 1,853,267 shares, ending with 9,460,939 shares worth about $465.95 million. Orbis Allan Gray Ltd trimmed its holding by 657,026 shares to finish with 5,449,161 shares valued at roughly $268.37 million. GSK plc kept its position steady at 3,220,627 shares worth about $158.62 million. SR One Capital Management, LP held onto 2,038,763 shares valued at roughly $100.41 million without changing its share count. Two Sigma Investments, LP grew its holdings by 505,572 shares, ending with 1,988,621 shares worth about $97.94 million.

CRISPR Therapeutics AG Stock Down 1.0%

The stock recently traded around $50.98 as of October 16, 2026, which is up about 1.5% since the insider sale. Shares sit below both the 50-day moving average of $54.99 and the 200-day moving average of $53.13. The stock trades closer to its 52-week low of $44.12 than its 52-week high of $75.06.

Recent Earnings

For its trailing twelve months, the company posted revenue of $13.39 million and an earnings per share loss of $4.74. The biotechnology firm recorded a year-over-year revenue growth rate of 1041.4% alongside a return on equity of negative 26.1%. Net profit margins sat at 0.0%. Investors look ahead to the company's next earnings report, which is scheduled for November 9, 2026.

Insider Buying and Selling at CRISPR Therapeutics AG

General Counsel James R. Kasinger sold 10,400 shares on September 22, 2026, for $626,460. Kasinger later sold 1,990 shares on October 6, 2026, for $119,481. On the same day as George's trade, CEO Samarth Kulkarni sold 4,098 shares for $201,867, and Kasinger sold another 1,040 shares for $51,230.

Analysts Set New Price Targets

On July 8, 2026, HC Wainwright & Co. reiterated a buy rating with an $80.00 price target. Citigroup maintained a buy rating on August 4, 2026, lifting its target from $82.00 to $88.00. Citizens reiterated a market outperform rating with an $80.00 target on August 25, 2026, and again on August 31, 2026. Needham reiterated a buy rating with an $82.00 target on August 31, 2026. The stock carries a consensus buy rating from 19 analysts with a mean price target of $85.63.

About CRISPR Therapeutics

CRISPR Therapeutics AG is a biotechnology enterprise based in Zug, Switzerland. The firm builds gene-based medicines utilizing its CRISPR/Cas9 platform to target serious human diseases by altering genomic DNA sequences.

Bottom Line

Investors will watch for the upcoming earnings report on November 9, 2026, for updates on the company's financial health and clinical pipeline progress. Further Form 4 filings will show whether other insiders continue adjusting their personal holdings.